Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by SetPoint Medical
SetPoint Medical Announces Filing of Premarket Approval (PMA) Application to the U.S. Food and Drug Administration (FDA) for Novel Neuroimmune Modulation Device for the Treatment of Rheumatoid Arthritis
December 09, 2024
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Announces Late-Breaking Data from RESET-RA Study at ACR Convergence 2024
November 18, 2024
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Receives FDA’s IDE Approval for U.S. Pilot Study of Neuroimmune Modulation Platform in Adults with Relapsing-Remitting Multiple Sclerosis
October 02, 2024
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Announces Positive Topline Results from Landmark RESET-RA Study Evaluating Neuroimmune Modulation for the Treatment of Rheumatoid Arthritis
July 10, 2024
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Accepted into FDA Total Product Life Cycle Advisory Program for Development of its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis
March 21, 2024
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Receives FDA Breakthrough Device Designation for its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis
March 13, 2024
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Announces Publication of Data for Neuroimmune Modulation to Treat Crohn's Disease in Journal of Crohn's and Colitis
October 03, 2023
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Appoints Rohan Seth as Chief Financial Officer
June 12, 2023
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Announces Expanded $65M Credit Facility to Support Development of the Company’s Novel Platform for Rheumatoid Arthritis
January 19, 2023
From
SetPoint Medical
Via
Business Wire
Tickers
RWAY
SetPoint Medical Announces $80M Preferred Stock Financing to Advance Company’s Novel Treatment for Autoimmune Diseases
January 19, 2023
From
SetPoint Medical
Via
Business Wire
First Patient Enrolled in Stage 2 of Pivotal Study of SetPoint Medical’s Pioneering Technology for the Treatment of Rheumatoid Arthritis
October 10, 2022
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Announces FDA Approval for Continuation of the RESET-RA Pivotal Study
September 13, 2022
From
SetPoint Medical
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.